BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld Asia
See today's BioWorld
Home
» Junshi taps Revitope in discovery stage to develop antibody-based cancer immunotherapies
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Junshi taps Revitope in discovery stage to develop antibody-based cancer immunotherapies
July 14, 2020
By
David Ho
and
Elise Mak
No Comments
BEIJING – Besides advancing its neutralizing antibodies for COVID-19, Shanghai Junshi Biosciences Co. Ltd. is aiming to expand its pipeline. On July 13, it entered a collaboration with Revitope Oncology Inc.
BioWorld
BioWorld Asia
Deals and M&A
China